1-6 of 6
Lu Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer

Free
Caiyun Wang, Tao Wang, Dacheng Lv, Ling Li, Jinnan Yue, Hong-Zhuan Chen, Lu Xu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2357–2367.
https://doi.org/10.1158/1535-7163.MCT-19-0181
Published: 02 December 2019
View article titled, Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer
Open the PDF for Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A030: Biomarker study of vantictumab plus paclitaxel in HER2- breast cancer patients

Free
Chun Zhang, William R. Henner, Min Wang, Fiore Cattaruzza, Pete Yeung, Gilbert O'Young, Yuwang Liu, Gretchen Argast, Lu Xu, Shailaja Uttamsingh, John Lewicki, Ann M. Kapoun
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A030.
https://doi.org/10.1158/1535-7163.TARG-17-A030
Published: 01 January 2018
View article titled, Abstract A030: Biomarker study of vantictumab plus paclitaxel in HER2- breast cancer patients
Journal Articles

Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors

Free
Pamela Munster, S. Gail Eckhardt, Amita Patnaik, Anthony F. Shields, Anthony W. Tolcher, S. Lindsey Davis, John V. Heymach, Lu Xu, Ann M. Kapoun, Leonardo Faoro, Jakob Dupont, Renata Ferrarotto
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C42.
https://doi.org/10.1158/1535-7163.TARG-15-C42
Published: 01 December 2015
View article titled, Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors
Journal Articles

Abstract B79: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors.

Free
David C. Smith, Michael Gordon, Wells Messersmith, Rashmi Chugh, David Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Rainer K. Brachmann, Antonio Jimeno
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B79.
https://doi.org/10.1158/1535-7163.TARG-13-B79
Published: 01 November 2013
View article titled, Abstract B79: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors.
Journal Articles

Abstract B24: Biomarker analysis in the first-in-human phase 1a study for vantictumab (OMP-18R5; anti-Frizzled) demonstrates pharmacodynamic (PD) modulation of the Wnt pathway in patients with advanced solid tumors.

Free
David C. Smith, Lee Rosen, Min Wang, Chun Zhang, Lu Xu, Rashmi Chugh, Anthony Tolcher, Jonathan Goldman, Jakob Dupont, Raiiner K. Brachmann, Kyriakos Papadopoulos, Ann M. Kapoun
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B24.
https://doi.org/10.1158/1535-7163.TARG-13-B24
Published: 01 November 2013
View article titled, Abstract B24: Biomarker analysis in the first-in-human phase 1a study for vantictumab (OMP-18R5; anti-Frizzled) demonstrates pharmacodynamic (PD) modulation of the Wnt pathway in patients with advanced solid tumors.
Journal Articles

Abstract B48: A first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors.

Free
S. Lindsey Davis, Patricia LoRusso, Lu Xu, Ann M. Kapoun, Jakob Dupont, Pamela Munster, S. Gail Eckhardt, Amita Patnaik
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B48.
https://doi.org/10.1158/1535-7163.TARG-13-B48
Published: 01 November 2013
View article titled, Abstract B48: A first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors.